<DOC>
	<DOCNO>NCT02144285</DOCNO>
	<brief_summary>The purpose study look tolerability safety LY3113593 . Study doctor see safe whether produce side effect follow single injection vein skin healthy participant ( Part A ) participants chronic kidney disease treat hemodialysis ( Part B ) . The study also measure much study drug get blood stream , long take body get rid study drug effect study drug body . This first time study drug give participant . This study research purpose intend treat medical condition . For participant , study last 85 day , include screen . Screening require within 28 day prior start study .</brief_summary>
	<brief_title>A Study LY3113593 Healthy Participants Participants With Chronic Kidney Disease Treated With Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Healthy Participants : Healthy male females Participants body mass index ( BMI ) 18.5 29.9 kilogram per meter square ( kg/m^2 ) , inclusive screening Participants Treated Hemodialysis : Participants male female endstage renal disease ( ESRD ) receive adequate maintenance hemodialysis ( 3 time weekly ) least 12 week prior screen Participants hemoglobin value greather equal ( ≥ ) 9.0 gram per deciliter ( g/dL ) less equal ( ≤ ) 12.5 g/dL screen Participants body mass index ( BMI ) 18.5 45.0 kg/m^2 , inclusive , screen Both Populations : Male participant agree use reliable method birth control avoid donate sperm study 3 month follow dose investigational product Female participant must childbearing potential Healthy Participants : Participants history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Participants use intend use overthecounter prescription medication , include herbal medication within 14 day prior dose Participants Treated Hemodialysis : Participants history myocardial infarction , acute coronary syndrome , stroke transient ischemic attack within prior 6 month Participants heart failure result dyspnea rest minimal exercise Participants poorly control hypertension Participants history significant thrombotic disease , pulmonary hypertension , significant hematological disease current liver disease , know hepatic biliary abnormality Participants blood transfusion within prior 12 week anticipate need blood transfusion study Participants evidence active peptic , duodenal , esophageal ulcer disease gastrointestinal bleeding within prior 12 week Both Populations : Participants know allergy related compound component study drug formulation , clinically significant multiple severe drug allergy , intolerance topical corticosteroid , severe post treatment hypersensitivity reaction history significant atopy Participants participate , within last 30 day ( 5 halflives long half life ) clinical trial involve investigational product Participants know ongoing psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Renal dialysis</keyword>
</DOC>